Compare Stocks: IRD, KLRA, COAG, and ANAB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$49.44 +6.1%	$53.58	$20.18 ▼ $72.36	$1.48B	0.76	682,820 shs	292,431 shs
COAG Hemab Therapeutics	$32.04 +6.6%	$40.88	$23.00 ▼ $55.42	$1.50B	N/A	379,132 shs	134,900 shs
IRD Opus Genetics	$3.80 -1.0%	$4.51	$1.70 ▼ $7.07	$312.83M	0.62	1.43 million shs	957,481 shs
KLRA Kailera Therapeutics	$11.56 +2.8%	$14.33	$9.76 ▼ $28.23	$1.50B	N/A	872,035 shs	410,098 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	0.00%	+1.44%	-15.56%	-7.32%	+34.59%
COAG Hemab Therapeutics	0.00%	-4.90%	-27.00%	-39.12%	+3,006,999,900.00%
IRD Opus Genetics	0.00%	-17.42%	-25.87%	+25.90%	+105.35%
KLRA Kailera Therapeutics	0.00%	-3.10%	-12.31%	-37.19%	+1,124,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$49.44 +6.1%	$53.58	$20.18 ▼ $72.36	$1.48B	0.76	682,820 shs	292,431 shs
COAG Hemab Therapeutics	$32.04 +6.6%	$40.88	$23.00 ▼ $55.42	$1.50B	N/A	379,132 shs	134,900 shs
IRD Opus Genetics	$3.80 -1.0%	$4.51	$1.70 ▼ $7.07	$312.83M	0.62	1.43 million shs	957,481 shs
KLRA Kailera Therapeutics	$11.56 +2.8%	$14.33	$9.76 ▼ $28.23	$1.50B	N/A	872,035 shs	410,098 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	0.00%	+1.44%	-15.56%	-7.32%	+34.59%
COAG Hemab Therapeutics	0.00%	-4.90%	-27.00%	-39.12%	+3,006,999,900.00%
IRD Opus Genetics	0.00%	-17.42%	-25.87%	+25.90%	+105.35%
KLRA Kailera Therapeutics	0.00%	-3.10%	-12.31%	-37.19%	+1,124,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANAB AnaptysBio	2.71	Moderate Buy	$77.79	57.32% Upside
COAG Hemab Therapeutics	2.67	Moderate Buy	$54.71	70.77% Upside
IRD Opus Genetics	2.89	Moderate Buy	$12.71	234.32% Upside
KLRA Kailera Therapeutics	2.75	Moderate Buy	$42.75	269.81% Upside

Current Analyst Ratings Breakdown

Latest IRD, KLRA, COAG, and ANAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/16/2026	IRD Opus Genetics	Citizens Jmp Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform	$17.00
10/15/2026	IRD Opus Genetics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	COAG Hemab Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$70.00
10/12/2026	COAG Hemab Therapeutics	Rodman & Renshaw Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$56.00
10/12/2026	COAG Hemab Therapeutics	Rodman & Renshaw Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$56.00
10/6/2026	KLRA Kailera Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D) ➝ Sell (D-)
10/6/2026	IRD Opus Genetics	JonesTrading Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$10.00 ➝ $17.00
10/2/2026	IRD Opus Genetics	Chardan Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$16.00
9/30/2026	ANAB AnaptysBio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$70.00 ➝ $60.00
9/25/2026	COAG Hemab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D+) ➝ Sell (D)
9/23/2026	ANAB AnaptysBio	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$90.00 ➝ $81.00

(Data available from 10/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANAB AnaptysBio	$234.60M	6.30	N/A	N/A	$1.34 per share	36.90
COAG Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
IRD Opus Genetics	$14.20M	22.14	N/A	N/A	$0.22 per share	17.29
KLRA Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANAB AnaptysBio	-$13.23M	$5.37	9.22	20.43	N/A	82.37%	112.00%	2.20%	11/3/2026 (Estimated)
COAG Hemab Therapeutics	N/A	-$24.78	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IRD Opus Genetics	-$49.59M	-$1.35	N/A	N/A	N/A	-1,091.82%	N/A	-150.13%	11/11/2026 (Estimated)
KLRA Kailera Therapeutics	-$148.96M	-$3,651.09	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest IRD, KLRA, COAG, and ANAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	IRD Opus Genetics	-$0.14	N/A	N/A	N/A	$1.55 million	N/A
11/3/2026	Q3 2026	ANAB AnaptysBio	-$1.84	N/A	N/A	N/A	$25.56 million	N/A
9/21/2026	Q2 2026	ANAB AnaptysBio	-$0.4650	$5.11	+$5.5750	$5.11	$14.06 million	$27.49 million
8/12/2026	Q2 2026	KLRA Kailera Therapeutics	-$0.74	-$1.09	-$0.35	-$1.09	N/A	N/A
8/11/2026	Q2 2026	COAG Hemab Therapeutics	-$0.63	-$0.80	-$0.17	-$0.80	N/A	N/A
8/6/2026	Q2 2026	IRD Opus Genetics	-$0.1567	-$0.14	+$0.0167	-$0.14	$2.63 million	$0.76 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
COAG Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A
IRD Opus Genetics	N/A	N/A	N/A	N/A	N/A
KLRA Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANAB AnaptysBio	N/A	7.58	7.58
COAG Hemab Therapeutics	N/A	35.85	35.85
IRD Opus Genetics	N/A	12.19	12.19
KLRA Kailera Therapeutics	N/A	11.11	11.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANAB AnaptysBio	N/A
COAG Hemab Therapeutics	N/A
IRD Opus Genetics	14.97%
KLRA Kailera Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ANAB AnaptysBio	31.50%
COAG Hemab Therapeutics	N/A
IRD Opus Genetics	11.70%
KLRA Kailera Therapeutics	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANAB AnaptysBio	104	29.90 million	20.48 million	Optionable
COAG Hemab Therapeutics	59	46.71 million	N/A	N/A
IRD Opus Genetics	28	82.65 million	72.98 million	N/A
KLRA Kailera Therapeutics	145	129.64 million	N/A	N/A

IRD, KLRA, COAG, and ANAB Headlines

Recent News About These Companies

Kailera Therapeutics (KLRA) Stock Forecast & Price Target

October 11, 2026 | investing.com

Kailera Therapeutics (NASDAQ:KLRA) Shares Climb 7.6% - Time to Buy?

October 9, 2026 | marketbeat.com

Kailera Therapeutics, Inc. (NASDAQ:KLRA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

October 9, 2026 | americanbankingnews.com

Kailera Therapeutics, Inc. (NASDAQ:KLRA) Stock Has Average Target Price of $42.75

October 9, 2026 | marketbeat.com

Kailera Therapeutics, Inc.'s (NASDAQ:KLRA) Lock-Up Period Will End on October 14th

October 7, 2026 | marketbeat.com

Kailera Therapeutics (NASDAQ:KLRA) Sets New 12-Month Low - Time to Sell?

October 5, 2026 | marketbeat.com

Kailera Therapeutics Inc Presents New Phase 1 Data For Ribupatide Injection At EASD 2026 Annual Meeting

October 1, 2026 | marketscreener.comM

Kailera Therapeutics (NASDAQ:KLRA) Stock Falls 5.6% - Should You Sell?

October 1, 2026 | marketbeat.com

Kailera Therapeutics Announces Phase 1 Ribupatide Data Showing Flexible Injection Sites and Additional Hengrui Pharma Clinical Presentations at EASD 2026

October 1, 2026 | quiverquant.comQ

Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting

October 1, 2026 | globenewswire.com

Kailera Therapeutics, Inc. Completes Enrollment In KaiNETIC Global Phase 3 Clinical Program Of Ribupatide Injection

September 30, 2026 | marketscreener.comM

Kailera Therapeutics Completes Enrollment for Trial of Ribupatide to Treat Obesity

September 30, 2026 | finance.yahoo.com

Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection

September 30, 2026 | globenewswire.com

Kailera Therapeutics (NASDAQ:KLRA) Hits New 12-Month Low - Here's Why

September 28, 2026 | marketbeat.com

868,160 Shares of Kailera Therapeutics, Inc. $KLRA Acquired by State Street Corp

September 26, 2026 | marketbeat.com

Why Kailera Therapeutics, Inc.’s (KLRA) Stock Is Down 10.13%

September 24, 2026 | aaii.comA

Kailera Therapeutics (NASDAQ:KLRA) Reaches New 12-Month Low - What's Next?

September 22, 2026 | marketbeat.com

Kailera Therapeutics (NASDAQ:KLRA) Shares Down 5.5% - Time to Sell?

September 21, 2026 | marketbeat.com

Kailera Therapeutics, Inc.(NasdaqGS:KLRA) added to S&P Biotechnology Select Industry Index

September 21, 2026 | marketscreener.comM

Kailera Therapeutics: Hold Due To Need For Progress On Weight Loss Differentiation

September 18, 2026 | seekingalpha.com

Kailera Therapeutics: An Outside Biotech Bet For The Next GLP-1 Obesity Drug Approval

September 17, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IRD, KLRA, COAG, and ANAB Company Descriptions

AnaptysBio NASDAQ:ANAB

$49.44 +2.83 (+6.08%)

As of 03:03 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Hemab Therapeutics NASDAQ:COAG

$32.04 +1.97 (+6.55%)

As of 02:45 PM Eastern

We are a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Coagulation disorders encompass a broad and heterogeneous group of conditions, and many patients experience significant life-long disease burden due to either a lack of available prophylactic therapies or limitations associated with existing treatment approaches. Our lead asset, sutacimig (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Our second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. We are also advancing multiple preclinical and discovery-stage assets. We estimate that there are approximately an aggregate of 10,000 patients with Glanzmann thrombasthenia and Factor VII deficiency and an aggregate of 120,000 patients with Von Willebrand Disease in the geographies where we intend to commercialize our assets, including the United States, the European Union, Japan, the Gulf Cooperation Council countries and other select regions. With greater disease burden awareness, potential regulatory approvals of new prophylactic options and expanding global reach of these options, we believe the overall number of addressable patients for our clinical-stage assets, and preclinical and discovery stage programs could be greater than we currently estimate. We aim to establish the industry’s leading coagulation franchise through the execution of our “Hemab 2x3 by 2030” strategic roadmap, which is designed to build a franchise consisting of 2 commercial medicines, 2 new late-stage clinical programs, and 2 new early-stage clinical programs by 2030. We have not yet initiated pivotal trials for any of our product candidates, and due to the novel and unproven nature of our programs, their current stage of development and the lack of approved prophylactic therapies to inform endpoint selection and trial design, we may not be able to achieve our strategic goals on the timeline we expect or at all. Our principal executive offices are located in Cambridge, MA.

Opus Genetics NASDAQ:IRD

$3.80 -0.04 (-0.96%)

As of 03:03 PM Eastern

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

Kailera Therapeutics NASDAQ:KLRA

$11.56 +0.31 (+2.76%)

As of 02:45 PM Eastern

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives. With our obesity-first focus, we have built a diversified pipeline of product candidates specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate that we believe offers the potential for the greatest weight loss. We are rapidly progressing four clinical-stage product candidates, leveraging multiple glucagon-like peptide-1, or GLP-1, based mechanisms of action and routes of administration. Our lead product candidate, ribupatide (also known as KAI-9531), is currently being evaluated in global Phase 3 trials as a once-weekly injectable GLP-1/glucose-dependent insulinotropic polypeptide, or GIP, receptor dual agonist peptide that we believe offers the potential for the greatest weight loss compared to all obesity management medications currently marketed or in development with a tolerability profile that is class-like or better. We are expanding our ribupatide franchise by developing a once-daily oral tablet formulation, oral ribupatide, based on the same peptide as injectable ribupatide, to provide a convenient oral option with the potential for highly differentiated tolerability with compelling weight loss among oral treatments. Additionally, we are advancing a second oral product candidate, KAI-7535, a once-daily small molecule GLP-1 receptor agonist with the potential to improve on the clinical profile of existing oral treatments. Finally, we are developing KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist, that leverages an incremental mechanism to potentially deliver compelling weight loss, improved liver fat reduction and a differentiated tolerability profile. KAI-4729 is based on a different peptide than injectable ribupatide and oral ribupatide. Obesity is a chronic, complex disease characterized by the accumulation of excessive body fat, resulting in significant negative impacts on health and quality of life. The most severely impacted patient population, people with a body mass index, or BMI, of 35 kg/m2 or greater, which we refer to as a BMI of 35+, represents the fastest growing and largest segment of this population, with half of U.S. adults with obesity expected to have a BMI of 35+ by 2030. While the approvals of GLP-1-based obesity management medications have changed the landscape of obesity management, there remains a critical need for medications offering greater weight loss, especially for those living with a higher BMI. For example, in the SURMOUNT-1 Phase 3 clinical trial, the majority of patients who had a baseline BMI of 35+ and were treated with tirzepatide, the most prescribed weight loss medicine today, were still living with obesity at the end of treatment. Both physicians and patients have identified expected weight loss as a primary treatment goal, with the magnitude of weight reduction serving as a crucial driver in therapy selection. We believe that injectable treatments will remain foundational for patients needing significant weight reduction. Meanwhile, for patients with a lower BMI, lower incidences of gastrointestinal side effects may be needed to achieve optimal weight loss and treatment persistence, and we believe oral treatments can unlock adoption for those with more modest weight loss needs, while also supporting the chronic treatment journey of those living with higher BMIs. We were originally incorporated under the laws of the State of Delaware on May 8, 2024 under the name Hercules CM Newco, Inc. We changed our name to Kailera Therapeutics, Inc. on August 22, 2024. Our principal executive offices are located in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IRD, KLRA, COAG, and ANAB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IRD, KLRA, COAG, and ANAB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IRD, KLRA, COAG, and ANAB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IRD, KLRA, COAG, and ANAB Company Descriptions

AnaptysBio NASDAQ:ANAB

Hemab Therapeutics NASDAQ:COAG

Opus Genetics NASDAQ:IRD

Kailera Therapeutics NASDAQ:KLRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IRD, KLRA, COAG, and ANAB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IRD, KLRA, COAG, and ANAB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IRD, KLRA, COAG, and ANAB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IRD, KLRA, COAG, and ANAB Company Descriptions

AnaptysBio NASDAQ:ANAB

Hemab Therapeutics NASDAQ:COAG

Opus Genetics NASDAQ:IRD

Kailera Therapeutics NASDAQ:KLRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools